Britain and America have hammered out a landmark trade agreement that will maintain zero duties on British drug shipments going into the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost funding on drugs through the National Health Service (NHS). This commitment secures that tariffs on these crucial exports will stay at zero for a duration of three years.
This deal comes after previous statements to significantly raise tariffs on branded drug products, with increases floated as high as 100%.
"This deal between the UK bolsters the international landscape for cutting-edge drugs and brings long-overdue equity to American-British drug exports," a statement said.
Commercial Significance
Pharmaceuticals represent one of the the United Kingdom's largest exports to the United States, which is by far the primary market for large UK drugmakers.
Export figures show that in the 12 months prior to September, the UK exported drugs valued at over eleven billion pounds to the US. This value represented a significant portion of British export trade in that span.
"This guarantee protects employment, increases capital expenditure and paves the way for the UK to emerge as a international leader for life sciences," the Business and Trade Secretary commented.
Detailed UK Commitments
The agreement includes several notable pledges from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to double overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. In the past, repayments topped twenty percent.
Industry Background
The pact comes amid a ongoing row between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by arguments that American consumers were charged a premium for the same drugs than people in the UK and Europe.
Recently, several significant drug company projects in the UK have been paused or abandoned, while substantial expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the past decade.
